Research programme: protein homeostasis therapeutics - Celgene Corporation/FORMA Therapeutics

Drug Profile

Research programme: protein homeostasis therapeutics - Celgene Corporation/FORMA Therapeutics

Latest Information Update: 13 Apr 2017

Price : $50

At a glance

  • Originator FORMA Therapeutics
  • Developer Celgene Corporation; FORMA Therapeutics
  • Class
  • Mechanism of Action Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Neurodegenerative disorders

Most Recent Events

  • 10 Apr 2017 Protein homeostasis therapeutics is still in early research for Cancer and Neurodegenerative disorders in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Neurodegenerative-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top